Aktis Oncology (NASDAQ:AKTS) Stock Price Down 6.6% – Here’s What Happened

Shares of Aktis Oncology (NASDAQ:AKTS) traded down 6.6% on Monday . The company traded as low as $25.91 and last traded at $26.0390. Approximately 62,182 shares traded hands during trading, a decline of 82% from the average session volume of 344,839 shares. The stock had previously closed at $27.88.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright raised their price target on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. JPMorgan Chase & Co. boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Raymond James Financial started coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price on the stock. Finally, William Blair initiated coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Aktis Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.60.

Aktis Oncology Price Performance

The company has a 50 day simple moving average of $23.01. The company has a market capitalization of $1.34 billion and a price-to-earnings ratio of -66.24.

Aktis Oncology (NASDAQ:AKTS) last released its earnings results on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million during the quarter. Sell-side analysts predict that Aktis Oncology will post -1.62 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.